BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022.

UroViu Corp has launched the new Hystero-V, a single-use hysteroscope compatible with UroViu’s Always Ready endoscopy platform.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation in-person of members of Sensorion’s senior management in the Inner Ear Disorder Therapeutics Summit, a scientific conference being held in Boston, USA, in June 2022.

Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and French pharmaceutical group Pierre Fabre announced that the companies have entered into a manufacturing agreement.

Zomedica Corp. announced it has signed a definitive agreement to acquire substantially all of the assets of Revo Squared LLC.

Third Rock Ventures today announced the closing of Third Rock Ventures Fund VI, raising $1.1 billion.

ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several key scientific conferences including the American Society for Nutrition.

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company presentation at BIO International Convention is now available at https://www.oncotelic.com/wp-content/uploads/2022/06/BIO-2022-digital-slides.pdf .

Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that Dr. Philip Toleikis, President & CEO of Sernova Corp, will be participating in the Truist Securities Cell Therapy Symposium, Symposia-cel being held in person at the Lotte New York Palace on Tuesday, June 28, 2022.

Marengo Therapeutics, Inc., a company pioneering novel therapeutics that directly target the Vβ chain of the T cell receptor (TCR) to activate the right T cell subsets to fight cancer, today announced the appointment of Svetlana Makhni as Chief Financial Officer, further bolstering Marengo’s C-suite leadership credentials.